ANTIBODIES AGAINST (1R,2R)-CYCLOHEXANEDIAMINEPLATINUM(II)-DNA ADDUCT RECOGNIZE THE CONFORMATIONAL DIFFERENCES OF ISOMERIC ANALOGS OF CYCLOHEXANEDIAMINE

被引:4
作者
YAMADA, H
KATO, T
HIROSE, J
INAGAKI, K
NOJI, M
KIDANI, Y
机构
[1] NAGOYA CITY UNIV,SCH MED,DEPT BIOREGULAT RES,KAWASUMI CHO,MIZUHO KU,NAGOYA,AICHI 467,JAPAN
[2] NAGOYA CITY UNIV,FAC PHARMACEUT SCI,NAGOYA,AICHI 467,JAPAN
关键词
Cisplatin; Cyclohexanediamineplatinum(II); DNA cross-linking; ELISA; Platinum-DNA adduct;
D O I
10.1016/0167-4781(90)90101-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Antibodies reactive to (1R,2R)-cyclohexanediamineplatinum(II)-DNA ((1R,2R)-cyclohexanediamine: 1R,2R-dach) adducts were elicited by immunization of rabbit with calf thymus DNA modified by Pt(1R,2R-dach)Cl2 at a ratio of bound platinum per nucleotide ( D N)b) of 0.0335. In an enzyme-linked immunosorbent assay (ELISA), the binding of specific antibodies to Pt(1R,2R-dach)-DNA adduct (60 μl of 1.235 · 10-7 M Pt in each wells) on the assay plate was competitively inhibited by Pt(1R,2R-dach)-DNA adduct ( D N)b = 0.0653) in the solution. Almost equal inhibition was observed with Pt(1S,2S-dach)-DNA (( D N)b = 0.0412), an optical isomer of 1R,2R-dach. Pt(1R,2S-dach)-DNA (( D N)b = 0.0371) and Pt(1R,3S-dach)-DNA (( D N)b = 0.0281) in which the cyclohexane ring is stereochemically perpendicular to the platinum chelate plane, also inhibited antibody binding, but these adducts gave only incomplete inhibition at higher Pt-DNA adduct concentrations. Although Pt(1R,2R-dach)-d(GpG) and Pt(1R,2R-dach)(NH3)2 inhibited antibody binding, the affinity of the antibody for Pt(1R,2R-dach)(NH3)2 was lower than with Pt(1R,2R-dach)-DNA, and the inhibition behavior of Pt(1R,2R-dach)-d(GpG) was biphasic, i.e., at the lower concentration the inhibition curve was consistent with that of Pt(1R,2R-dach)-DNA, but at the higher concentration it shifted to that of Pt(1R,2R-dach)(NH3)2. The affinity of the antibody for cis-DDP was markedly lower than with Pt(1R,2R-dach)(NH3)2. These facts suggest that the antibodies may bind to the substituents (the platinum and its surroundings) of the various Pt complexes rather than the DNA structure altered by platinum binding. © 1990.
引用
收藏
页码:298 / 302
页数:5
相关论文
共 19 条
[1]  
BENZOFSKY JA, 1981, MOL IMMUNOL, V18, P751
[2]   ADDUCTS OF THE ANTITUMOR DRUG CIS-DIAMMINEDICHLOROPLATINUM(II) WITH DNA - FORMATION, IDENTIFICATION, AND QUANTITATION [J].
FICHTINGERSCHEPMAN, AMJ ;
VANDERVEER, JL ;
DENHARTOG, JHJ ;
LOHMAN, PHM ;
REEDIJK, J .
BIOCHEMISTRY, 1985, 24 (03) :707-713
[3]  
HSU IC, 1981, CANCER RES, V41, P1091
[4]  
INAGAKI K, 1985, CHEM PHARM BULL, V33, P5593
[5]   DIFFERENCES IN BINDING OF (1,2-CYCLOHEXANEDIAMINE)PLATINUM(II) ISOMERS WITH D(GPG) [J].
INAGAKI, K ;
KIDANI, Y .
INORGANIC CHEMISTRY, 1986, 25 (01) :1-3
[6]   ANTI-TUMOR ACTIVITY OF 1,2-DIAMINOCYCLOHEXANE-PLATINUM COMPLEXES AGAINST SARCOMA-180 ASCITES FORM [J].
KIDANI, Y ;
INAGAKI, K ;
IIGO, M ;
HOSHI, A ;
KURETANI, K .
JOURNAL OF MEDICINAL CHEMISTRY, 1978, 21 (12) :1315-1318
[7]  
KIDANI Y, 1977, Journal of Clinical Hematology and Oncology, V7, P197
[8]  
KIDANI Y, 1976, GANN, V67, P921
[9]  
LIPPARD SJ, 1983, BIOCHEMISTRY-US, V22, P5165, DOI 10.1021/bi00291a016
[10]  
MALFOY B, 1981, CANCER RES, V41, P4127